Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.79 |
| ▸ | RAB9A | P51151 | 4/20 | 0.79 |
| ▸ | RECQL | P46063 | 2/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29707208 | 1.00 | NPC1 (0.79) | NPC1RAB9ARECQLALDH1A1KMT2A | |
| SCHEMBL1942075 | 0.91 | NPC1 (0.77) | NPC1RAB9ARECQLALDH1A1KMT2A | |
| SCHEMBL28087012 | 0.90 | NPC1 (0.74) | NPC1RAB9ARECQLALDH1A1KMT2A | |
| SCHEMBL9187561 | 0.89 | NPC1 (1.00) | NPC1RAB9ARECQLALDH1A1KMT2A | |
| SCHEMBL16056223 | 0.88 | NPC1 (0.72) | NPC1RAB9ARECQLALDH1A1KMT2A | |
| SCHEMBL9642715 | 0.87 | NPC1 (0.89) | NPC1RAB9ARECQLALDH1A1KMT2A | |
| SCHEMBL3647420 | 0.86 | NPC1 (0.59) | NPC1RAB9ARECQLALDH1A1KMT2A | |
| SCHEMBL2307746 | 0.85 | RAB9A (0.72) | NPC1RAB9ARECQLALDH1A1KMT2A | |
| SCHEMBL13531827 | 0.84 | NPC1 (0.89) | NPC1RAB9ARECQLALDH1A1KMT2A | |
| SCHEMBL13435257 | 0.84 | NPC1 (0.89) | NPC1RAB9ARECQLALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220296722-A1 | CONJUGATES AND CONJUGATES FOR USE IN PREVENTING OR TREATING OF BRAIN DAMAGE AND NEURODEGENERATIVE DISEASES | MEDICORTEX FINLAND OY (FI) | 2022-09-22 | — | — | US | disclosed |
| EP-4021510-A2 | CONJUGATES AND CONJUGATES FOR USE IN PREVENTING OR TREATING OF BRAIN DAMAGE AND NEURODEGENERATIVE DISEASES | Medicortex Finland Oy (FI) | 2022-07-06 | — | — | EP | disclosed |
| EP-3958851-A1 | ALLOSTERIC ACTIVATORS OF THE ALPHA IA-ADRENERGIC RECEPTOR | The Cleveland Clinic Foundation (US) | 2022-03-02 | — | — | EP | disclosed |
| CN-108947907-B | Azobenzene-linked cyclic N-heterocyclic carbene silver complex and preparation method and application thereof | 天津师范大学 | 2021-06-25 | — | — | CN | disclosed |
| CN-108947907-B | Azobenzene-linked cyclic N-heterocyclic carbene silver complex and preparation method and application thereof | 天津师范大学 | 2021-06-25 | — | — | CN | disclosed |
| WO-2021038125-A2 | CONJUGATES AND CONJUGATES FOR USE IN PREVENTING OR TREATING OF BRAIN DAMAGE AND NEURODEGENERATIVE DISEASES | MEDICORTEX FINLAND OY (FI) | 2021-03-04 | — | — | WO | disclosed |
| WO-2020219720-A1 | ALLOSTERIC ACTIVATORS OF THE ALPHA1A -ADRENERGIC RECEPTOR | THE CLEVELAND CLINIC FOUNDATION (US) | 2020-10-29 | — | — | WO | disclosed |
| US-20200087326-A1 | DEEP RED FLUORESCENT PROBE | THE UNIVERSITY OF TOKYO (JP) | 2020-03-19 | — | — | US | disclosed |
| US-20200087326-A1 | DEEP RED FLUORESCENT PROBE | THE UNIVERSITY OF TOKYO (JP) | 2020-03-19 | — | — | US | disclosed |
| CN-107353209-B | There are the two phenoxy group flexible molecules and its preparation method and application of high-affinity with A β plaque block | 北京师范大学 | 2019-07-19 | — | — | CN | disclosed |
| US-6124323-A | ACTIVE DRUG TREATING STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMIOGLYCOSIDE ANTIBIOTICS-INDUCED HEARING LOSS, MIGRAINE HEADACHES, CHRONIC PAIN, GLAUCOMA, CMV RETINITIS, PSYCHOSIS | WARNER-LAMBERT COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| EP-0990643-A1 | Luminescence indicator for determining calcium ions | AVL Medical Instruments (CH) | 2000-04-05 | — | — | EP | disclosed |
| EP-0869792-A4 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 1999-09-22 | — | — | EP | disclosed |
| US-5885997-A | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-03-23 | — | — | US | disclosed |
| EP-0869792-A2 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997023216-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
| EP-0245997-B1 | N-SUBSTITUTED P-AMINOETHYLSULPHON ANILIDES AS ANTIARRHYTHMIC AGENTS, AND INTERMEDIATES THEREFOR | Pfizer Limited (GB) | 1992-04-15 | — | — | EP | disclosed |
| US-5079248-A | Antifibrillatory agents; side effect reduction | PFIZER INC. (US) | 1992-01-07 | — | — | US | disclosed |
| US-4959366-A | Anti-arrhythmic agents | PFIZER INC. (US) | 1990-09-25 | — | — | US | disclosed |
| EP-0245997-A2 | N-substituted p-aminoethylsulphon anilides as antiarrhythmic agents, and intermediates therefor | Pfizer Limited (GB) | 1987-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087326-A1 | DEEP RED FLUORESCENT PROBE | CASR, NCS1, CHERP | NPC1 533/4885RAB9A 484/4885RECQL 2409/4885 |
| US-20220296722-A1 | CONJUGATES AND CONJUGATES FOR USE IN PREVENTING OR TREATING OF BRAIN DAMAGE AND NEURODEGENERATIVE DISEASES | BDNF, PYGB, SI | NPC1 864/4885RAB9A 1820/4885RECQL 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.